Tag: Kanser - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Altai Protocol Library | October 4, 2021

New Drug: Cabozantinib for differentiated thyroid cancer

Study: Double-blind, randomized Phase III trial (COSMIC-311) RAI-refractory differentiated thyroid cancer pts with prior lenvatinib or sorafenib Cabozantinib 60 mg daily vs. placebo Efficacy: ORR: 18% vs. 0% Median PFS:

Altai Protocol Library | October 4, 2021

New Drug: Tisotumab vedotin for advanced cervical cancer

Study: Open-label, single-arm Phase II trial (innovaTV 204) Recurrent/metastatic squamous cell, adenoCa or adenosquamous cervical cancer, progressed on/after doublet chemo Tisotumab vedotin 2 mg/kg (max 200 mg) q21 (N=102) Efficacy: